132 related articles for article (PubMed ID: 18971047)
1. Regarding "Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions".
Dindyal S; Sharma P; Kyriakides C
J Vasc Surg; 2008 Nov; 48(5):1357; author reply 1357. PubMed ID: 18971047
[No Abstract] [Full Text] [Related]
2. Drug-eluting stenting for femoropopliteal lesions, followed by cilostazol treatment, reduces stent restenosis in patients with symptomatic peripheral artery disease.
Zen K; Takahara M; Iida O; Soga Y; Kawasaki D; Nanto S; Yokoi H; Matoba S;
J Vasc Surg; 2017 Mar; 65(3):720-725. PubMed ID: 28073668
[TBL] [Abstract][Full Text] [Related]
3. Sustained Effectiveness of Cilostazol After Endovascular Treatment of Femoropopliteal Lesions: Midterm Follow-up From the Sufficient Treatment of Peripheral Intervention by Cilostazol (STOP-IC) Study.
Soga Y; Hamasaki T; Edahiro R; Iida O; Inoue N; Suzuki K; Yokoi Y; Kawasaki D; Zen K; Urasawa K; Aodo K;
J Endovasc Ther; 2018 Jun; 25(3):306-312. PubMed ID: 29706129
[TBL] [Abstract][Full Text] [Related]
4. Prevention of Femoropopliteal In-Stent Restenosis With Cilostazol: A Meta-Analysis.
Iftikhar O; Oliveros K; Tafur AJ; Casanegra AI
Angiology; 2016 Jul; 67(6):549-55. PubMed ID: 26390878
[TBL] [Abstract][Full Text] [Related]
5. Impact of cilostazol on angiographic restenosis after balloon angioplasty for infrapopliteal artery disease in patients with critical limb ischemia.
Soga Y; Iida O; Kawasaki D; Hirano K; Yamaoka T; Suzuki K
Eur J Vasc Endovasc Surg; 2012 Dec; 44(6):577-81. PubMed ID: 23107298
[TBL] [Abstract][Full Text] [Related]
6. Drug-Coated Balloons for Complex Femoropopliteal Lesions: 2-Year Results of a Real-World Registry.
Schmidt A; Piorkowski M; Görner H; Steiner S; Bausback Y; Scheinert S; Banning-Eichenseer U; Staab H; Branzan D; Varcoe RL; Scheinert D
JACC Cardiovasc Interv; 2016 Apr; 9(7):715-24. PubMed ID: 27056311
[TBL] [Abstract][Full Text] [Related]
7. Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions.
Iida O; Nanto S; Uematsu M; Morozumi T; Kitakaze M; Nagata S
J Vasc Surg; 2008 Jul; 48(1):144-9. PubMed ID: 18482817
[TBL] [Abstract][Full Text] [Related]
8. Mid-term clinical outcome and predictors of vessel patency after femoropopliteal stenting with self-expandable nitinol stent.
Soga Y; Iida O; Hirano K; Yokoi H; Nanto S; Nobuyoshi M
J Vasc Surg; 2010 Sep; 52(3):608-15. PubMed ID: 20573476
[TBL] [Abstract][Full Text] [Related]
9. Balloon angioplasty compared with stenting for treatment of femoropopliteal occlusive disease: a meta-analysis.
Mwipatayi BP; Hockings A; Hofmann M; Garbowski M; Sieunarine K
J Vasc Surg; 2008 Feb; 47(2):461-9. PubMed ID: 17950563
[TBL] [Abstract][Full Text] [Related]
10. Invited commentary.
Rasmussen TE
J Vasc Surg; 2009 Sep; 50(3):548. PubMed ID: 19700092
[No Abstract] [Full Text] [Related]
11. Outcomes of endovascular interventions for TASC II B and C femoropopliteal lesions.
Baril DT; Marone LK; Kim J; Go MR; Chaer RA; Rhee RY
J Vasc Surg; 2008 Sep; 48(3):627-33. PubMed ID: 18727966
[TBL] [Abstract][Full Text] [Related]
12. Endovascular interventions for TASC II D femoropopliteal lesions.
Baril DT; Chaer RA; Rhee RY; Makaroun MS; Marone LK
J Vasc Surg; 2010 Jun; 51(6):1406-12. PubMed ID: 20385464
[TBL] [Abstract][Full Text] [Related]
13. Late outcomes of balloon angioplasty and angioplasty with selective stenting for superficial femoral-popliteal disease are equivalent.
Nguyen BN; Conrad MF; Guest JM; Hackney L; Patel VI; Kwolek CJ; Cambria RP
J Vasc Surg; 2011 Oct; 54(4):1051-1057.e1. PubMed ID: 21636240
[TBL] [Abstract][Full Text] [Related]
14. The effect of cilostazol on late outcomes after endovascular treatment for occlusive femoropopliteal disease.
Wang C; Du Z; Zhang M
J Vasc Surg; 2024 Jul; 80(1):291-292. PubMed ID: 38906666
[No Abstract] [Full Text] [Related]
15. Clinical evaluation of a paclitaxel-eluting balloon for treatment of femoropopliteal arterial disease: 12-month results from a multicenter Italian registry.
Micari A; Cioppa A; Vadalà G; Castriota F; Liso A; Marchese A; Grattoni C; Pantaleo P; Cremonesi A; Rubino P; Biamino G
JACC Cardiovasc Interv; 2012 Mar; 5(3):331-8. PubMed ID: 22440500
[TBL] [Abstract][Full Text] [Related]
16. Effects of probucol versus aspirin and versus brachytherapy on restenosis after femoropopliteal angioplasty: the PAB randomized multicenter trial.
Gallino A; Do DD; Alerci M; Baumgartner I; Cozzi L; Segatto JM; Bernier J; Tutta P; Kellner F; Triller J; Schneider E; Amann-Vesti B; Studer G; Jäger K; Aschwanden M; Canevascini R; Jacob AL; Kann R; Greiner R; Mahler F
J Endovasc Ther; 2004 Dec; 11(6):595-604. PubMed ID: 15615549
[TBL] [Abstract][Full Text] [Related]
17. Restenosis after percutaneous transluminal angioplasty in the femoropopliteal segment: the role of inflammation.
Schillinger M; Haumer M; Schlerka G; Mlekusch W; Exner M; Ahmadi R; Minar E
J Endovasc Ther; 2001 Oct; 8(5):477-83. PubMed ID: 11718406
[TBL] [Abstract][Full Text] [Related]
18. Cutting balloon versus conventional balloon angioplasty in short femoropopliteal arterial stenoses.
Cotroneo AR; Pascali D; Iezzi R
J Endovasc Ther; 2008 Jun; 15(3):283-91. PubMed ID: 18540701
[TBL] [Abstract][Full Text] [Related]
19. Commentary: Outback catheter in femoropopliteal subintimal angioplasty: new horizons in treating chronic total occlusions.
Setacci C; Sirignano P; Setacci F
J Endovasc Ther; 2011 Feb; 18(1):22-4. PubMed ID: 21314344
[No Abstract] [Full Text] [Related]
20. Excimer laser with adjunctive balloon angioplasty and heparin-coated self-expanding stent grafts for the treatment of femoropopliteal artery in-stent restenosis: twelve-month results from the SALVAGE study.
Laird JR; Yeo KK; Rocha-Singh K; Das T; Joye J; Dippel E; Reddy B; Botti C; Jaff MR
Catheter Cardiovasc Interv; 2012 Nov; 80(5):852-9. PubMed ID: 22422738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
